Qiao Wenliang, Wang Lijiao, Luo Youfu, Yang Tao
Lung Cancer Center, Laboratory of Lung Cancer, and Laboratory of Human Diseases and Immunotherapies, West China Hospital, Sichuan University, Chengdu, 610041, China.
College of Food and Bioengineering, Xihua University, Sichuan, 610039, China.
Eur J Med Chem. 2025 Mar 5;285:117267. doi: 10.1016/j.ejmech.2025.117267. Epub 2025 Jan 12.
The increasing threat of antibiotic resistance has necessitated the development of new antibacterial agents. 33 novel antibacterial agents have been approved by the U.S. Food and Drug Administration (FDA) within the two-decade timeframe from 2003 to 2023. These novel antibacterial agents included new chemical classes, such as lipopeptides, 18-membered macrolides, diaromatic quinolones, and nitroimidazoles, as well as modified existing classes, such as quinolones, tetracyclines, β-lactams, macrolides, oxazolidinones, and aminoglycosides. Nonetheless, during these twenty years, approval for new antibiotics was notably absent in 6 different years, and the total number of antibiotics approved was considerably less than that of other drug classes, including anticancer drugs. In this review, we provide an extensive analysis of the synthetic approaches and therapeutic applications of these approved antibacterial agents. We believe that this review will help further research on potential antibacterial agents for clinical use and development of next generation of antibacterial agents.
抗生素耐药性威胁日益增加，因此有必要开发新型抗菌药物。在2003年至2023年的二十年时间框架内，美国食品药品监督管理局（FDA）已批准了33种新型抗菌药物。这些新型抗菌药物包括新的化学类别，如脂肽、18元大环内酯类、二芳基喹诺酮类和硝基咪唑类，以及对现有类别进行修饰的药物，如喹诺酮类、四环素类、β-内酰胺类、大环内酯类、恶唑烷酮类和氨基糖苷类。尽管如此，在这二十年中，有6年明显没有新抗生素获批，且获批抗生素的总数远少于包括抗癌药物在内的其他药物类别。在本综述中，我们对这些已获批抗菌药物的合成方法和治疗应用进行了广泛分析。我们相信，本综述将有助于进一步研究潜在的临床用抗菌药物以及开发新一代抗菌药物。
